Plain-English translation of NCT07303790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early exploratory trial testing GC012F, a new type of cell therapy designed to treat multiple sclerosis. The study will evaluate whether this treatment is safe and well-tolerated, and whether it helps control MS symptoms. Researchers will also study how the body processes and responds to the medication over time.
Multiple sclerosis can be difficult to control with current standard treatments, especially for patients who have tried other strong medications without success. This trial is exploring whether this new cell-based approach might offer a new option for people whose MS continues to worsen despite existing treatments.
You likely qualify if…
You likely don't qualify if…
You will undergo screening tests including blood work and brain imaging to confirm you qualify. If accepted, you may receive a procedure called apheresis to collect certain cells from your blood, followed by possible pre-treatment to prepare your body. You will then receive a single infusion of the new medication. After that, you'll have regular follow-up visits for 3 years to monitor safety and how well the treatment works, with additional long-term follow-up for up to 15 years total.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China